PL2349346T3 - Sposób metronomicznego dawkowania proleków kamptotecynowych (np. PEG-irynotekan) - Google Patents

Sposób metronomicznego dawkowania proleków kamptotecynowych (np. PEG-irynotekan)

Info

Publication number
PL2349346T3
PL2349346T3 PL09789364T PL09789364T PL2349346T3 PL 2349346 T3 PL2349346 T3 PL 2349346T3 PL 09789364 T PL09789364 T PL 09789364T PL 09789364 T PL09789364 T PL 09789364T PL 2349346 T3 PL2349346 T3 PL 2349346T3
Authority
PL
Poland
Prior art keywords
irinotecan
peg
metronomic dosing
camptothecin prodrugs
camptothecin
Prior art date
Application number
PL09789364T
Other languages
English (en)
Inventor
Michael A. Eldon
Shibani S. Harite
Tamra L. Barker
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of PL2349346T3 publication Critical patent/PL2349346T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
PL09789364T 2008-09-23 2009-09-23 Sposób metronomicznego dawkowania proleków kamptotecynowych (np. PEG-irynotekan) PL2349346T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9951608P 2008-09-23 2008-09-23
US10693108P 2008-10-20 2008-10-20
US17343309P 2009-04-28 2009-04-28
EP09789364.8A EP2349346B1 (en) 2008-09-23 2009-09-23 Method of metronomic dosing with camptothecin prodrugs (e.g. peg-irinotecan)
PCT/US2009/005284 WO2010036335A1 (en) 2008-09-23 2009-09-23 Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Publications (1)

Publication Number Publication Date
PL2349346T3 true PL2349346T3 (pl) 2020-03-31

Family

ID=41268391

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09789364T PL2349346T3 (pl) 2008-09-23 2009-09-23 Sposób metronomicznego dawkowania proleków kamptotecynowych (np. PEG-irynotekan)

Country Status (21)

Country Link
US (3) US8906353B2 (pl)
EP (1) EP2349346B1 (pl)
JP (3) JP2012503602A (pl)
KR (1) KR20110063457A (pl)
CN (1) CN102164617A (pl)
AU (1) AU2009297091B2 (pl)
CA (1) CA2736939C (pl)
CY (1) CY1122208T1 (pl)
DK (1) DK2349346T3 (pl)
ES (1) ES2744975T3 (pl)
HR (1) HRP20192120T1 (pl)
HU (1) HUE047352T2 (pl)
IL (1) IL211888A (pl)
LT (1) LT2349346T (pl)
MX (1) MX2011003063A (pl)
PL (1) PL2349346T3 (pl)
PT (1) PT2349346T (pl)
RS (1) RS59607B1 (pl)
SI (1) SI2349346T1 (pl)
SM (1) SMT201900609T1 (pl)
WO (1) WO2010036335A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009297091B2 (en) 2008-09-23 2015-03-05 Nektar Therapeutics Compositions and methods for achieving sustained therapeutic drug concentrations in a subject
ES2779225T3 (es) * 2011-04-08 2020-08-14 Sphaera Pharma Pte Ltd Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos
MX366911B (es) * 2012-11-28 2019-07-30 Nektar Therapeutics Método para evaluar y predecir la eficacia del tratamiento del cáncer de mama con un inhibidor de topoisomerasa i de acción prolongada.
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
CN114224865A (zh) 2016-06-02 2022-03-25 因华生技制药股份有限公司 供癌症医疗的节拍式口服吉西他宾
CN106539557A (zh) * 2016-10-08 2017-03-29 西安交通大学 一种基于恒速静脉输入的药代动力学参数的测定方法
JP7546552B2 (ja) 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
EP4297746A4 (en) * 2021-02-23 2024-12-04 Edison Oncology COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC BENEFITS OF SUBOPTIMIALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASE
CN115317486B (zh) * 2022-08-17 2024-04-19 南昌大学 一种共载紫杉醇和伊立替康前药纳米制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024476A1 (en) 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
TW438775B (en) 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CZ297979B6 (cs) 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
CA2369999A1 (en) 1999-04-28 2000-11-02 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
CA2416511C (en) 2000-07-21 2012-05-08 Martin D. Hurlimann Nuclear magnetic resonance methods for extracting information about a fluid in a rock
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7401013B2 (en) 2001-10-15 2008-07-15 Lockheed Martin Corporation Method to optimize test data
JP2005508365A (ja) 2001-10-29 2005-03-31 ネクター セラピューティックス エイエル,コーポレイション プロテインキナーゼcインヒビターのポリマー結合体
CA2464346A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
RU2004139090A (ru) 2002-06-06 2005-06-10 Юниверсити Оф Вашингтон (Us) Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
BR122012021252B8 (pt) 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
LT1675622T (lt) 2003-09-17 2017-09-11 Nektar Therapeutics Daugiašakio polimero provaistai
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
AU2008213576B2 (en) * 2007-02-09 2013-01-17 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
CN101199857B (zh) * 2007-12-12 2011-04-13 中国药科大学 mPEG-PLA-喜树碱类药物的结合物
AU2009297091B2 (en) 2008-09-23 2015-03-05 Nektar Therapeutics Compositions and methods for achieving sustained therapeutic drug concentrations in a subject

Also Published As

Publication number Publication date
WO2010036335A1 (en) 2010-04-01
US9801873B2 (en) 2017-10-31
DK2349346T3 (da) 2019-10-07
IL211888A0 (en) 2011-06-30
US10525051B2 (en) 2020-01-07
HUE047352T2 (hu) 2020-04-28
EP2349346A1 (en) 2011-08-03
PT2349346T (pt) 2019-10-24
AU2009297091A1 (en) 2010-04-01
CY1122208T1 (el) 2020-11-25
JP2015034180A (ja) 2015-02-19
ES2744975T3 (es) 2020-02-27
MX2011003063A (es) 2011-04-21
RS59607B1 (sr) 2020-01-31
LT2349346T (lt) 2019-09-25
CN102164617A (zh) 2011-08-24
IL211888A (en) 2015-08-31
US8906353B2 (en) 2014-12-09
US20110269789A1 (en) 2011-11-03
CA2736939C (en) 2021-09-14
US20180028525A1 (en) 2018-02-01
CA2736939A1 (en) 2010-04-01
JP6076317B2 (ja) 2017-02-08
KR20110063457A (ko) 2011-06-10
US20150087668A1 (en) 2015-03-26
JP2012503602A (ja) 2012-02-09
SMT201900609T1 (it) 2020-01-14
HRP20192120T1 (hr) 2020-02-21
EP2349346B1 (en) 2019-08-28
SI2349346T1 (sl) 2019-12-31
JP2016216510A (ja) 2016-12-22
AU2009297091B2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
HUE047352T2 (hu) Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
AP3408A (en) Tobacco curing method
GB0822893D0 (en) Advanced speed profiles - Further updates
IL209382A0 (en) Water-soluble acetaminophen analogs
HUE036937T2 (hu) Neodímiummal katalizált polibutadién
GB2462829B (en) Measurement method
GB0803107D0 (en) Method
EP2336393A4 (en) GALVANOPLASTY PROCESS
GB0810418D0 (en) Method
GB0804981D0 (en) Method
ZA201009263B (en) Plant regulatory sequences
GB0807409D0 (en) Method
GB0804690D0 (en) Method
EP2239093A4 (en) PRODUCTION INSTALLATION
GB0807410D0 (en) Method
EP2309852A4 (en) NOVEL PROCEDURE
GB0809404D0 (en) Method
EP2321435A4 (en) WIEDERAUFKOHLUNGSVERFAHREN
GB0805862D0 (en) Method
AU326445S (en) Meter
GB0806186D0 (en) Method
GB0908678D0 (en) Metering apparatus
GB0810116D0 (en) Method
GB0804242D0 (en) Clopidogrel solution
GB0812957D0 (en) Quwb-it (game)